MacroGenics | MGNX - Fremdkapital





Fremdkapital Veränderung Datum
AbbVie USD 58.94B 4.03B 2025-12
Amgen USD 51.89B 1.88B 2026-03
AstraZeneca USD 25.96B 177M 2026-03
Biogen USD 6.29B 1.7M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Daiichi Sankyo JPY 300.15B 199.41B 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Genmab DKK 5.14B 5.01B 2025-12
Geron USD 119.83M 286K 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
J&J USD 37.53B 1.91B 2026-03
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
MacroGenics USD 70M 256K 2025-12
Merck USD 46.67B 77M 2026-03
Pfizer USD 60.57B 1.08B 2026-03
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Xencor USD 82.12M 5.64M 2026-03